Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Mayer on the Optimization of SERDs in ER+ Breast Cancer

July 15th 2021

Dr. Mayer discusses the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palbociclib, and details future research efforts with SERDs.

Future Directions in HER2-Positive Metastatic Breast Cancer

July 15th 2021

Sara A. Hurvitz, MD, reviews therapy options for patients with HER2-positive metastatic breast cancer and comments on emerging therapeutic strategies.

Treatment Sequencing for HER2-Positive Metastatic Breast Cancer

July 15th 2021

Sara A. Hurvitz, MD, comments on her preferences for treating patients with HER2-positive metastatic breast cancer and shares her strategy for sequencing therapies.

Adverse Events in HER2-Positive Metastatic Breast Cancer Treatment

July 15th 2021

Recommendations for mitigating and managing common treatment-related adverse events associated with tucatinib, trastuzumab, and capecitabine based on safety data from HER2CLIMB.

Updated Results from HER2CLIMB and Tucatinib Use in Patient Subgroups

July 15th 2021

Combination therapy with tucatinib, trastuzumab, and capecitabine shows efficacy in all patient populations studied.

Tucatinib for HER2-Positive Metastatic Breast Cancer

July 15th 2021

Efficacy of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer, including patients with brain metastases or visceral disease.

Treatment Options in HER2-Positive Metastatic Breast Cancer

July 15th 2021

An overview of treatment options for HER2-positive metastatic breast cancer and practical guidance on selecting therapy.

Case Discussion: Resistance to CDK4/6 Inhibitors in HR+ mBC

July 14th 2021

Andrew D. Seidman, MD, presents a case study of a 56-year-old postmenopausal woman diagnosed with stage IIB HR+ breast cancer and leads the discussion on approaching treatment for the given patient.

Implications of PIK3CA Mutations in HR+ mBC

July 14th 2021

Dejan Juric, MD, leads the discussion on the role of PIK3CA mutations in HR+ metastatic breast cancer.

Updates in HER2+ MBC: The NALA and SOPHIA Trials

July 13th 2021

Dr Lee Schwartzberg, MD, FASCO, highlights the appropriateness for treating HER2-positive metastatic breast cancer with either neratinib plus capecitabine or margetuximab plus chemotherapy based on evidence revealed by the NALA and SOPHIA clinical trials.

Implications of DESTINY-Breast01 in HER2+ MBC

July 13th 2021

Considerations for initiating trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who received previous treatment with trastuzumab emtansine based on data demonstrated by the DESTINY-Breast01 study.

CDK4/6 Inhibitors Show Hints of Activity in Early-Stage HR+/HER2- Breast Cancer

July 12th 2021

Halle Moore, MD, discusses the data that support the use of CDK4/6 inhibitors plus endocrine therapy in HR-positive, HER2-negative breast cancer, how to select between available CDK4/6 inhibitors in the metastatic setting, and the current state of this treatment approach for patients with early-stage disease.

Mature Data Drive New Insights With Novel Agents in Breast Cancer

July 9th 2021

The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates, and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic.

Final Thoughts

July 9th 2021

Nicholas McAndrew, MD, MSCE, provides final thoughts on findings reported at ASCO 2021 for patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.

Real-World Clinical Outcomes With Alpelisib in HR+/HER2-/PIK3CA-Mutated Advanced Breast Cancer

July 9th 2021

Nicholas McAndrew, MD, MSCE, provides his perspective on real-world clinical outcomes using alpelisib in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.

BYLieve: CDK4/6 Treatment Duration and Alpelisib Benefit in HR+/HER2-/PIK3CA-Mutated Advanced Breast Cancer

July 9th 2021

Nicholas McAndrew, MD, MSCE, discusses the impact of CDK4/6 therapy duration on alpelisib benefit in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer from the BYLieve trial.

SOLAR-1 and CBYL719X2101: Alpelisib + Fulvestrant in HR+/HER2-/PIK3CA-Mutated Advanced Breast Cancer

July 9th 2021

Nicholas McAndrew, MD, MSCE, reviews PIK3CA mutations in HR+/HER2- breast cancer and provides his perspective on the joint analysis of SOLAR-1 and CBYL719X2101 in which patients were given alpelisib and fulvestrant.

Survival Advantages in Metastatic Breast Cancer Move the Needle Toward Curative-Intent Strategies

July 8th 2021

Heather L. McArthur, MD, MPH, discusses key advances in breast cancer regarding CDK4/6 inhibitors, PI3K inhibitors, and subcutaneous formulations of standard treatments.

Selecting a CDK4/6 Inhibitor for HR+ mBC

July 7th 2021

Experts in breast cancer comment on the appropriate patient selection of CDK4/6 inhibitors for the management of HR-positive metastatic breast cancer.

Using CDK4/6 Inhibitors in First-Line Treatment of HR+ mBC

July 7th 2021

A review of data from key phase 3 clinical trials, including ASCO 2021 updates, assessing the use of CDK4/6 inhibitors with endocrine therapy for the frontline treatment of HR-positive metastatic breast cancer.